Credence Wire Journalist
Zara Hussain
Biotech & Life Sciences Reporter
Reports on CRISPR, longevity science, synthetic biology, and the coming convergence of AI and drug discovery. Based in San Francisco.
Articles by Zara
3 storiesGoogle DeepMind's AlphaFold 3 Predicts New Class of Cancer-Killing Protein Structures
Researchers have used AlphaFold 3 to computationally design protein structures that selectively induce apoptosis in pancreatic cancer cell lines, a breakthrough that could reshape oncology drug pipelines.
CRISPR-Based Gene Therapy Achieves Functional Cure in 97% of Sickle Cell Patients in 18-Month Trial
A Phase III trial of 340 patients across 12 centers shows that a single infusion of the CRISPR-edited therapy results in sustained elevation of fetal hemoglobin in 97.3% of participants, eliminating vaso-occlusive crises in the majority of patients.
Altos Labs' Epigenetic Reprogramming Therapy Reverses Biological Age by 25 Years in Human Trial
In the first peer-reviewed human longevity intervention study, 40 participants receiving partial epigenetic reprogramming showed measurable reversal of aging biomarkers across 14 tissue types, with no serious adverse events reported over 18 months.
Free Daily Briefing
The Signal Brief
The most important stories, every morning.
Join 140,000+ professionals who start their day with Credence Wire.
Free. No spam. Unsubscribe anytime.